ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0503 • ACR Convergence 2020

    Targeted Metabolomic Profiling and Prediction of Cardiovascular Events: A Prospective Study of Patients with Psoriatic Arthritis and Psoriasis

    Keith Colaco1, Ker-Ai Lee2, Shadi Akhtari3, Raz Winer4, Paul Welsh5, Naveed Sattar5, Iain McInnes6, Vinod Chandran7, Paula Harvey8, Richard Cook2, Dafna Gladman7, Vincent Piguet8 and Lihi Eder9, 1Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Women's College Hospital, University of Toronto, North York, ON, Canada, 4Rambam Health Care Campus, Haifa, Israel, 5University of Glasgow, Glasgow, Scotland, United Kingdom, 6Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 7Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 8Women's College Hospital, University of Toronto, Toronto, ON, Canada, 9Women’s College Research Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis and psoriasis, collectively termed psoriatic disease (PsD), are associated with increased cardiovascular (CV) risk. Metabolites comprise biomarkers that may add predictive value…
  • Abstract Number: 0517 • ACR Convergence 2020

    Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study

    Thomas Garvey1, Cynthia Crowson2, Matthew J. Koster3 and Kenneth Warrington3, 1Mayo Clinic Rochester, Apple Valley, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 3Mayo Clinic, Rochester, MN

    Background/Purpose: Diagnostic methods for giant cell arteritis (GCA) have evolved over recent decades, and large vessel imaging plays an increasing role in disease detection.   The…
  • Abstract Number: 0516 • ACR Convergence 2020

    Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial

    Sebastian Unizony1, Shalini V. Mohan2, Jian Han2 and John H. Stone1, 1Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 2Genentech, South San Francisco, CA

    Background/Purpose: To investigate the characteristics of disease flare after successful treatment with tocilizumab (TCZ) in patients with giant cell arteritis (GCA).Methods: We performed a post…
  • Abstract Number: 0522 • ACR Convergence 2020

    Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase III Case Collection Results

    Medha Barbhaiya1, Stephane Zuily2, Yasaman Ahmadzadeh3, Karen Costenbader4, Raymond Naden5 and Doruk Erkan6, 1Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, 2Nancy Academic Hospital, Vandoeuvre-l�Nancy, France, 3Hospital for Special Surgery, New York, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand, 6Hospital for Special Surgery, New York, NY

    Background/Purpose: An international multi-disciplinary effort is underway to develop rigorous, new, consensus- and evidence-based classification criteria for Antiphospholipid Syndrome (APS). The methodological approach includes four…
  • Abstract Number: 0521 • ACR Convergence 2020

    Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?

    Flavio Signorelli1, Gustavo Balbi2, Eloisa Bonfa3, Eduardo Borba4 and Danieli Andrade5, 1Universidade de São Paulo, Rio de janeiro, Rio de Janeiro, Brazil, 2Universidade de São Paulo, Juiz de Fora, Minas Gerais, Brazil, 3Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5University of Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…
  • Abstract Number: 0527 • ACR Convergence 2020

    Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience

    Nancy Agmon-Levin1, Mark Berman2, Liora Harel3, Merav Lidar4, Soad Hajyahia1 and Daphna Paran5, 1Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, 4Rheumatology unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Hod Hasharon, Israel, 5Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel

    Background/Purpose: The clinical manifestations of the antiphospholipid syndrome (APS) are heterogeneous and related to anti-phospholipid antibodies (aPL). There is some evidence that B cells are…
  • Abstract Number: 0529 • ACR Convergence 2020

    A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies

    Savino Sciascia1, Massimo Radin1, Irene Cecchi1, Daniela Rossi1 and Dario Roccatello2, 1University of Torino, Torino, Italy, 2S Giovanni Hospital, Univ of Turin, Turin, Italy

    Background/Purpose: Prospective data confirming the role of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in the absence of other aPL tested by β2–glycoprotein I-depend assays are missing.Methods: Since 2015 aPSPT…
  • Abstract Number: 0524 • ACR Convergence 2020

    Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases

    Yann Nguyen1, Cécile Yelnik2, Nathalie Morel3, Romain Paule4, Pierre-Yves Hatron2, Romain Stammler5, Léo Plaçais3, Jean-Charles Piette6, Luc Mouthon7, Eric Hachulla8, Marc Lambert2, Le Guern Véronique3 and Nathalie Costedoat-Chalumeau9, 11Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, 2Department of Internal Medicine and Clinical Immunology, National Referral Centre for rare Systemic Auto-immune Diseases North and North-West of France (CeRAINO), CHU Lille, Hôpital Claude Huriez, Lille, France, Lille, France, 3National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, France, 4Department of Internal Medicine, Hôpital Foch, Suresnes, France, Suresnes, France, 5National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, 6Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, 7National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, 8Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, 9APHP, Université de Paris, Paris, France

    Background/Purpose: Antiphospholipid syndrome (APS) is a heterogeneous disease, with different phenotypes which may widely vary from classical thrombotic or obstetrical manifestations to catastrophic antiphospholipid syndrome…
  • Abstract Number: 0519 • ACR Convergence 2020

    Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid

    Rohan Willis1, E Nigel Harris2, Vijaya Murthy3, Zurina Romay-Penabad1, Alvaro Schleh4, Monica Smikle2, Karel De Ceulaer2, Anne Tebo5, Troy Jaskowski6, Marta Guerra7, David Ware Branch8, Jane Salmon7, Michelle Petri9 and Emilio Gonzalez1, 1University of Texas Medical Branch, Galveston, TX, 2University of the West Indies, Kingston, Jamaica, 3University of Texas Medical Branch, League City, TX, 4Antiphospholipid Standardization Laboratory, GALVESTON, TX, 5Department of Pathology, University of Utah, Salt Lake City, 6ARUP Laboratories, Salt Lake City, UT, 7Hospital for Special Surgery, New York, NY, 8University of Utah, Salt Lake City, 9Johns Hopkins University School of Medicine, Baltimore

    Background/Purpose: Criteria antiphospholipid (aPL) antibodies that identify antiphospholipid syndrome (APS) patients, anticardiolipin (aCL) and anti-β2glycoprotein-I (anti-β2GPI), have demonstrated inconsistent specificity and sensitivity in this regard…
  • Abstract Number: 0532 • ACR Convergence 2020

    State-Specific Percentage of Adults with Arthritis Who Report Both Severe Joint Pain and Physical Inactivity and Their Characteristics, United States, Behavioral Risk Factor Surveillance System, 2017

    Dana Guglielmo1, Louise Murphy1, Jennifer Hootman1, Michael Boring1, Kristina Theis1, Charles Helmick1, Susan Carlson1, Yong Liu1, Hua Lu1 and Janet Croft1, 1Centers for Disease Control and Prevention, Atlanta, GA

    Background/Purpose: About one in four (27%) US adults with arthritis have severe joint pain, and only 36% meet the Physical Activity Guidelines for Americans. While…
  • Abstract Number: 0535 • ACR Convergence 2020

    Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists

    Jasvinder Singh1, John Richards2, Elizabeth Chang3, Toupin-April, Karine Toupin-April4 and Jennifer Barton5, 1University of Alabama at Birmingham, Birmingham, AL, 2Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 3Phoenix VA Medical Center, Phoenix, AZ, Phoenix, AZ, 4VA Portland Oregon, Portland, OR, 5Oregon University, Portland, OR

    Background/Purpose: To assess rheumatologists’ views and practices related to shared decision making (SDM) in gout treatment.Methods: We performed a cross-sectional electronic survey of rheumatologists at…
  • Abstract Number: 0536 • ACR Convergence 2020

    Systematic Geriatric Assessment in Older Patients with Rheumatic Diseases – The RheuMAGIC Pilot Study

    Bjoern Buehring1, Anna Berrisch2, Ioana Andreica3, Styliani Tsiami4, David Kiefer3, Uta Kiltz2, Xenofon Baraliakos2 and Juergen Braun2, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Velbert, Germany, 2Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 3Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Current demographic data predict that the number of older adults with rheumatic diseases will considerably increase in the coming years. Geriatric patients differ from…
  • Abstract Number: 0531 • ACR Convergence 2020

    The Prevalence of Systemic Sclerosis, Dermatomyositis/Polymyositis, and Giant Cell Arteritis in the United States by Race and Ethnicity: An Analysis Using Electronic Health Records

    Sunali Goonesekera1, Ankit Bansal1, Swarali Tadwalkar2 and Alison Isherwood3, 1Decision Resources Group, Part of Clarivate, Boston, MA, 2Decision Resources Group, part of Clarivate, Bangolore, India, 3Decision Resources Group, part of Clarivate, London, United Kingdom

    Background/Purpose: Epidemiological studies suggest differences in the prevalence and disease severity of certain autoimmune diseases by race and ethnicity. In this study, we evaluate the…
  • Abstract Number: 0539 • ACR Convergence 2020

    Sports with a Bat or Racket Are Not Associated with Thumb-base Osteoarthritis: Data from the Osteoarthritis Initiative

    Jeffrey Driban1, Grace Lo2, Mary Roberts3, Matthew Harkey4, Lena Schaefer5, Ida Kristin Haugen6, Stacy Smith7, Jeffrey Duryea7, Bing Lu8, Charles Eaton9, Marc Hochberg10, Rebecca Jackson11, C. Kent Kwoh12, Michael Nevitt13 and Timothy McAlindon1, 1Tufts Medical Center, Boston, MA, 2Michael E. Debakey VA Medical Center, Baylor College of Medicine, Houston, TX, 3Center for Primary Care & Prevention, Alpert Medical School of Brown University, Pawtucket, RI, 4University of Massachusetts, Worcester, MA, 5Radiology Department, Klinikum Nürnberg Süd, Nürnberg, Germany, 6Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 7Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 8Brigham and Women's Hospital and Harvard Medical School, Newton, MA, 9Brown University, Pawtucket, RI, 10University of Maryland School of Medicine, Baltimore, MD, 11Ohio State University, Columbus, OH, 12University of Arizona of Arizona Arthritis Center and Division of Rheumatology, College of Medicine, University of Arizona, Tucson, AZ, 13Department of Epidemiology and Biostatistics, University of California San Francisco, Orinda, CA

    Background/Purpose: Sports that require the use of a racket or bat to propel a ball (e.g., baseball, softball, tennis) expose the thumb-base to repetitive high-velocity…
  • Abstract Number: 0534 • ACR Convergence 2020

    National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use

    Meghna Jani1, Belay Yimer1, Therese Sheppard1, Mark Lunt1 and William Dixon1, 1Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Physician prescribing behaviour has been described as a key driver of rising opioid prescriptions and long-term opioid use. However, the effect of prescribers requires…
  • « Previous Page
  • 1
  • …
  • 660
  • 661
  • 662
  • 663
  • 664
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology